<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#" xmlns:NCBITaxon="http://purl.obolibrary.org/obo/NCBITaxon#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:obo="http://purl.obolibrary.org/obo/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:ncbitaxon="http://purl.obolibrary.org/obo/ncbitaxon#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>                               NIH Public Access <br />                                Author Manuscript <br />                                Mol Microbiol. Author manuscript; available PMC 2010 May 27. <br />                            Published final edited form as: <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                             Mol Microbiol. 2008 April ; 68(1): 37&#8211;50. doi:10.1111/j.1365-2958.2008.06131.x. <br />  <br />  <br />  <br />                            Characterization <span id='am-73' about='obo:NCBITaxon_5690' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_33682 obo:NCBITaxon_5654 obo:NCBITaxon_2759 obo:NCBITaxon_5653'><span id='am-74' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-75'  ></span><span id='am-76' property="rdfs:label" content="Trypanosoma" datatype="xsd:string"></span><span id='am-77' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>Trypanosoma</span> brucei dihydroorotate <br />                            dehydrogenase possible drug target; structural, kinetic and <br />                            RNAi studies <br />  <br />                            Tracy L Arakaki*,1,2, Frederick S Buckner*,2,3, J Robert Gillespie3, Nicholas A Malmquist4, <br />                            Margaret A Phillips4, Oleksandr Kalyuzhniy1,2, Joseph R Luft2,5, George T DeTitta2,5, <br />                            Christophe L M J Verlinde1,2, Wesley C Van Voorhis2,3, Wim G J Hol1,2, Ethan A <br />                            Merritt1,2,&#8224; <br />                            1Department Biochemistry, University Washington, Seattle, WA 98195 USA <br />  <br />                            2Structural   Genomics Pathogenic Protozoa (SGPP), www.sgpp.org <br />                            3Department      Medicine, University Washington, Seattle, WA 98195 USA <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                            4Department Pharmacology, University Texas Southwestern Medical Center, Dallas, TX 75390 <br />  <br />                            USA <br />                            5Hauptman      Woodward Institute, Buffalo, NY USA <br />  <br />                            Abstract <br />                                  Nucleotide biosynthesis pathways reported essential protozoan pathogens. <br />                                  Hence, evaluated essentiality enzyme pyrimidine biosyn-thetic pathway, <br />                                  dihydroorotate dehydrogenase (DHODH) eukaryotic parasite <span id='am-78' about='obo:NCBITaxon_5691' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_39700 obo:NCBITaxon_33682 obo:NCBITaxon_5654 obo:NCBITaxon_5690 obo:NCBITaxon_2759 obo:NCBITaxon_5653'><span id='am-79' property="oboInOwl:hasRelatedSynonym" content="Trypanosoma (Trypanozoon) brucei" datatype="xsd:string"></span><span id='am-80' property="oboInOwl:hasRelatedSynonym" content="Trypanosoma brucei subgroup" datatype="xsd:string"></span><span id='am-81' property="rdfs:label" content="Trypanosoma brucei" datatype="xsd:string"></span><span id='am-82' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-83'  ></span><span id='am-84' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>Trypanosoma brucei</span> through <br />                                  gene knockdown studies. RNAi knockdown DHODH expression bloodstream-form T. brucei <br />                                  did inhibit growth normal medium, profoundly retarded growth pyrimidine-depleted <br />                                  media presence known pyrimidine uptake antagonist 5-fluoruracil (5-FU). These <br />                                  results significant implications development therapeutics combat T. brucei <br />                                  infection. Specifically, combination therapy including T. brucei-specific DHODH inhibitor plus <br />                                  5-FU prove effective therapeutic strategy. We trypanosomal enzyme <br />                                  inhibited known inhibitors bacterial <span id='am-109' about='obo:NCBITaxon_class' typeof='owl:Thing NCBITaxon:_taxonomic_rank'><span id='am-110' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-111' property="rdfs:label" content="class" datatype="xsd:string"></span>Class</span> 1A DHODH, distinction sensitivity of <br />                                  DHODH human higher eukaryotes. <span id='am-112' about='obo:NCBITaxon_169495' typeof='owl:Thing obo:NCBITaxon_33340 obo:NCBITaxon_33213 obo:NCBITaxon_169440 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_7147 obo:NCBITaxon_43733 obo:NCBITaxon_33154 obo:NCBITaxon_43738 obo:NCBITaxon_480117 obo:NCBITaxon_33317 obo:NCBITaxon_169449 obo:NCBITaxon_480118 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_6960 obo:NCBITaxon_43750 obo:NCBITaxon_33208 obo:NCBITaxon_85512 obo:NCBITaxon_197562 obo:NCBITaxon_197563 obo:NCBITaxon_7203 obo:NCBITaxon_6656 obo:NCBITaxon_7496 obo:NCBITaxon_1206794 obo:NCBITaxon_88770 obo:NCBITaxon_33392 obo:NCBITaxon_169455 obo:NCBITaxon_50557 obo:NCBITaxon_43741'><span id='am-113' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-114' property="rdfs:label" content="This" datatype="xsd:string"></span><span id='am-115'  ></span><span id='am-116' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>This</span> selectivity supported crystal <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                  structure T. brucei enzyme, reported resolution 1.95 &#197;. Additional research, <br />                                  guided crystal structure described herein, needed identify potent inhibitors T. brucei <br />                                  DHODH. <br />  <br />  <br />                            Keywords <br />                                  flavoprotein; pyrimidine biosynthesis; gene knockdown; kinetoplastid; RNAi <br />  <br />  <br />                            INTRODUCTION <br />                                             Pyrimidine biosynthesis vital biological process, achieved novo synthesis and <br />                                             pyrimidine salvage pathways. However, parasitic protozoa deficient pyrimidine <br />  <br />                            &#8224; <br />                             Correspondence to: Ethan A Merritt, Dept Biochemistry, Box 357742, University Washington, Seattle, WA 98195. Phone: (206) <br />                            543-1421; Fax: (206) 685-7002; merritt@u.washington.edu. <br />                            *Contributed equally <br />                             Arakaki et al.                                                                                              Page 2 <br />  <br />  <br />                                             salvage (Chaudhary Roos, 2005) enzymes pyrimidine synthesis pathway <br />                                             considered potential drug targets. The fourth enzyme pathway is <br />                                             dihydroorotate dehydrogenase (DHODH), oxidizes dihydroorotate orotate, first <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             aromatic intermediate pathway, consequent transfer electrons protein <br />                                             cofactor FMN (Figure 1). Recent experiments validate DHODH drug target in <br />                                             <span id='am-68' about='obo:NCBITaxon_5693' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_33682 obo:NCBITaxon_5654 obo:NCBITaxon_5690 obo:NCBITaxon_2759 obo:NCBITaxon_47570 obo:NCBITaxon_5653'><span id='am-69' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-70'  ></span><span id='am-71' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-72' property="rdfs:label" content="Trypanosoma cruzi" datatype="xsd:string"></span>Trypanosoma cruzi</span> showed insect-stage epimastigotes dependent novo synthesis <br />                                             pyrimidines (Annoura et al., 2005). Specifically, gene interruption gene loci <br />                                             encoding cytosolic DHODH T. cruzi led cell non-viability; addition pyrimidine <br />                                             nucleosides medium did rescue DHODH knockdown cells. We therefore <br />                                             undertook extensive investigation essentiality closely homologous gene <br />                                             T. brucei, causative agent African Sleeping Sickness. <br />  <br />                                             DHODHs categorized classes, Class 1 Class 2, based sequence, <br />                                             localization cell, <span id='am-161' about='obo:NCBITaxon_1118549' typeof='owl:Thing obo:NCBITaxon_33213 obo:NCBITaxon_8936 obo:NCBITaxon_1329799 obo:NCBITaxon_1 obo:NCBITaxon_32523 obo:NCBITaxon_131567 obo:NCBITaxon_32524 obo:NCBITaxon_436489 obo:NCBITaxon_117570 obo:NCBITaxon_89593 obo:NCBITaxon_7742 obo:NCBITaxon_117571 obo:NCBITaxon_57387 obo:NCBITaxon_33154 obo:NCBITaxon_8782 obo:NCBITaxon_436486 obo:NCBITaxon_1338369 obo:NCBITaxon_8287 obo:NCBITaxon_2759 obo:NCBITaxon_8492 obo:NCBITaxon_6072 obo:NCBITaxon_33511 obo:NCBITaxon_33208 obo:NCBITaxon_7711 obo:NCBITaxon_8825 obo:NCBITaxon_7776 obo:NCBITaxon_436492 obo:NCBITaxon_32561 obo:NCBITaxon_8457 obo:NCBITaxon_436491'><span id='am-162' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-163' property="rdfs:label" content="Electron" datatype="xsd:string"></span><span id='am-164'  ></span><span id='am-165' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>electron</span> acceptor used reoxidize FMN second half- <br />                                             reaction (Nielsen, Andersen Jensen, 1996; Nielsen, Rowland, Larsen Jensen, 1996). <br />                                             Both classes belong Pfam sequence <span id='am-65' about='obo:NCBITaxon_family' typeof='owl:Thing NCBITaxon:_taxonomic_rank'><span id='am-66' property="rdfs:label" content="family" datatype="xsd:string"></span><span id='am-67' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>family</span> PF01180. Class 1 DHODHs primarily <br />                                             bacterial. They cytosolic divided 1A (E.C. 1.3.3.1) 1B (E.C. 1.3.1.14) <br />                                             depending electron acceptor oligomeric state. Class 2 DHODHs, including the <br />                                             human plasmodial enzymes, monomeric contain mitochondrial targeting sequences <br />                                             located N-terminal domain (Rowland et al., 2000). Furthermore, the <br />                                             inner membrane mitochondria (Knecht et al., 1996) associated cytoplasmic <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             membranes case E. coli (Karibian, 1978). Specific inhibitors known both <br />                                             classes (Palfey et al., 2001; Baldwin et al., 2005). <br />  <br />                                             We present genomic, biochemical, structural evidence TbDHODH Class 1A <br />                                             DHODH, particular inhibited Class 1A specific inhibitors. The structural <br />                                             analysis based 1.95&#197; resolution crystal structure T. brucei enzyme co-crystallized <br />                                             reaction product orotate. We present kinetic, inhibition, biophysical, RNAi <br />                                             knockdown <span id='am-172' about='obo:NCBITaxon_1369087' typeof='obo:NCBITaxon_37567 owl:Thing obo:NCBITaxon_33340 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_85604 obo:NCBITaxon_104431 obo:NCBITaxon_33154 obo:NCBITaxon_37570 obo:NCBITaxon_41191 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_6960 obo:NCBITaxon_33208 obo:NCBITaxon_41196 obo:NCBITaxon_197562 obo:NCBITaxon_85512 obo:NCBITaxon_197563 obo:NCBITaxon_95182 obo:NCBITaxon_41197 obo:NCBITaxon_6656 obo:NCBITaxon_7496 obo:NCBITaxon_7088 obo:NCBITaxon_1206794 obo:NCBITaxon_88770 obo:NCBITaxon_7100 obo:NCBITaxon_33392 obo:NCBITaxon_50557'><span id='am-173' property="rdfs:label" content="Data" datatype="xsd:string"></span><span id='am-174'  ></span><span id='am-175' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-176' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>data</span> T. brucei DHODH, previously characterized. <br />                                             Furthermore RNAi knockdown T. brucei DHODH synergistic the <br />                                             effects 5-fluorouracil (5-FU), inhibitor pyrimidine uptake T. brucei (de Koning and <br />                                             Jarvis, 1998). This finding provides rationale develop DHODH inhibitors be <br />                                             used combination 5-FU inhibitor pyrmidine uptake yield potent <br />                                             regimen. We encouraged structure inhibition studies offer insight the <br />                                             stereochemical functional details active site trypanosomal enzyme, may <br />                                             facilitate development lead compounds anti-trypanosomal drug discovery. Because <br />                                             results essentiality enzyme divergent reported closely <br />                                             related T. cruzi parasite, underscore importance validating anti-protozoan drug <br />                                             targets separately target organism (Wang,1997). <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               RESULTS <br />                                             Only DHODH gene T. brucei genome (GeneDB Tb927.5.3830). This <br />                                             gene initially identified structural genomics target (TargetDB Tbru015978) the <br />                                             Structural Genomics Pathogenic Protozoa consortium (SGPP). At time work was <br />                                             initiated trypanosomal DHODH structures available, preliminary <br />                                             characterization <span id='am-85' about='obo:NCBITaxon_5664' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_38581 obo:NCBITaxon_131567 obo:NCBITaxon_5658 obo:NCBITaxon_33682 obo:NCBITaxon_1286322 obo:NCBITaxon_5654 obo:NCBITaxon_2759 obo:NCBITaxon_38568 obo:NCBITaxon_5653'><span id='am-86' property="rdfs:label" content="Leishmania major" datatype="xsd:string"></span><span id='am-87' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-88' property="oboInOwl:hasRelatedSynonym" content="Leishmania tropica major" datatype="xsd:string"></span><span id='am-89'  ></span><span id='am-90' property="oboInOwl:hasRelatedSynonym" content="Leishmania (Leishmania) major" datatype="xsd:string"></span><span id='am-91' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>Leishmania major</span> DHODH presented (Feliciano et al., 2006) and <br />                                             preliminary crystallization T. cruzi enzyme reported (Inaoka et al., 2005). Thus <br />                                             undertook novo crystallographic structure determination T. brucei DHODH, and <br />                                             undertook biochemical characterization enzyme confirm assignment the <br />                                             trypanosomal enzymes Class 1A. <br />  <br />  <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 May 27. <br />                             Arakaki et al.                                                                                             Page 3 <br />  <br />  <br />                               Structural analysis <br />                                             The crystal structure TbDHODH determined 1.95&#197; resolution single crystal <br />                                             space group C2221. Consistent previously determined structures sequence <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             family, overall fold TbDHODH monomer &#945;&#946; barrel prosthetic FMN <br />                                             group located near C-terminus (Figure 2a). <br />  <br />                                             The asymmetric unit crystal structure contains monomers arranged two <br />                                             distinct dimers. The monomers dimer related two-fold symmetry dimer <br />                                             overlays L. lactis 1A dimer. The area contact dimer interface 2300 <br />                                             &#197;2 analyzed PDBsum (Laskowski et al., 2005). The interface includes 19 inter-monomer <br />                                             hydrogen bonds salt bridge Glu208 monomer A Lys297 monomer B. <br />                                             This salt bridge observed L. lactis structure. Lys297 strictly conserved among <br />                                             Class 1A DHODHs; residue 208 conserved glutamate aspartate (Fig. S2). Thus, <br />                                             salt bridge characteristic feature dimer interface Class 1A DHODHs. <br />  <br />                                             The oligomeric state protein examined analytical ultracentrifugation. TbD- <br />                                             HODH observed protein absorption 280 nm FMN absorption 454 nm. <br />                                             Throughout centrifugation experiments, single ideal <span id='am-122' about='obo:NCBITaxon_species' typeof='owl:Thing NCBITaxon:_taxonomic_rank'><span id='am-123' property="rdfs:label" content="species" datatype="xsd:string"></span><span id='am-124' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>species</span> model consistently yielded an <br />                                             average mass indicative dimeric enzyme, monomer/dimer model reliably produced <br />                                             sub-micromolar dissociation constants dimerization (Fig. S1). This biophysical result <br />                                             supports crystallographic observation TbDHODH homodimer. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             The TbDHODH structure contains <span id='am-156' about='obo:NCBITaxon_245896' typeof='owl:Thing obo:NCBITaxon_33340 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_71527 obo:NCBITaxon_41084 obo:NCBITaxon_33154 obo:NCBITaxon_219428 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_6960 obo:NCBITaxon_6072 obo:NCBITaxon_33208 obo:NCBITaxon_197562 obo:NCBITaxon_85512 obo:NCBITaxon_197563 obo:NCBITaxon_6656 obo:NCBITaxon_41088 obo:NCBITaxon_7496 obo:NCBITaxon_577181 obo:NCBITaxon_1206794 obo:NCBITaxon_88770 obo:NCBITaxon_33392 obo:NCBITaxon_50557 obo:NCBITaxon_7041'><span id='am-157' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-158' property="rdfs:label" content="Cis" datatype="xsd:string"></span><span id='am-159' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-160'  ></span>cis</span>-peptides, Glu56-Pro57 Cys193-Val194. These <br />                                             cis-peptides observed structures L. lactis 1A, L. lactis 1B, human Class <br />                                             2 homologs. The residues following cis-peptide, Arg58 Tyr59, close <br />                                             proximity active site highly conserved Class 1A DHODH sequences. No <br />                                             exceptional stereochemistry observed refined TbDHODH model. <br />  <br />                               FMN binding site <br />                                             The FMN prosthetic group located near dimer interface pocket formed predominantly <br />                                             strands &#946;4, &#946;6&#8211;7, &#946;11, &#946;17. FMN forms hydrogen bonds residues Ala20, Ser45, <br />                                             Lys44, Cys249, Val194, Lys165 (Fig. S3); hydrophobic interactions residues <br />                                             Ala19, Gly21, Met70, Tyr59, Asn68, orotate. The isoalloxazine ring FMN the <br />                                             aromatic ring orotate parallel other DHODH-orotate structures. The <br />                                             dimethylbenzene moiety isoalloxazine ring lacks close contacts residue <br />                                             solvent accessible. This differs FMN binding site human structure (25% <br />                                             sequence identity), Class 2-specific N-terminal domain blocks access active <br />                                             site. There similar hydrogen bonding interactions FMN TbDHODH and <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             human structures residues conserved structures Lys44 <br />                                             Cys249. The sulfhydryl Cys249 forms hydrogen bond O3 ribityl group of <br />                                             FMN. The equivalent interaction absent human structure, one <br />                                             hydrogen bond O3. In sequence-based structure alignment, Lys44 <span id='am-42' about='obo:NCBITaxon_3846' typeof='owl:Thing obo:NCBITaxon_78536 obo:NCBITaxon_3814 obo:NCBITaxon_1 obo:NCBITaxon_72025 obo:NCBITaxon_131567 obo:NCBITaxon_3803 obo:NCBITaxon_3398 obo:NCBITaxon_1437183 obo:NCBITaxon_33090 obo:NCBITaxon_163735 obo:NCBITaxon_91827 obo:NCBITaxon_131221 obo:NCBITaxon_71240 obo:NCBITaxon_58024 obo:NCBITaxon_1437201 obo:NCBITaxon_58023 obo:NCBITaxon_91835 obo:NCBITaxon_2759 obo:NCBITaxon_35493 obo:NCBITaxon_71275 obo:NCBITaxon_3193'><span id='am-43' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-44' property="rdfs:label" content="Glycine" datatype="xsd:string"></span><span id='am-45' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-46'  ></span>glycine</span> human <br />                                             structure nearby lysine (hLys100), forms hydrogen bonds O4 the <br />                                             isoalloxazine ring plays role binding FMN. <br />  <br />                                             Of residues TbDHODH form hydrophobic interactions FMN, are <br />                                             different human protein. These differences potential use designing an <br />                                             inhibitor targeting FMN binding site differential specificity human and <br />                                             trypanosomal enzymes. <br />  <br />  <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 May 27. <br />                             Arakaki et al.                                                                                               Page 4 <br />  <br />  <br />                               Orotate binding site conserved motifs Class 1A DHODH <br />                                             Class 1 Class 2 DHODHs differ active site base responsible abstraction a <br />                                             proton C5 orotate. In Class 1A DHODHs base cysteine; Class 2 enzymes, <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             including human DHODH, serine (N&#248;rager et al., 2003). In TbDHODH, S&#947; active <br />                                             site base Cys131 3.65 &#197; away C5 orotate. This distance slightly longer the <br />                                             3.3 &#197; observed L. lactis DHODH:orotate structure. In present crystal structure pH <br />                                             4 cysteine sulfur likely protonated. Residues 126&#8211;143, spanning region either <br />                                             active site Cys, strongly conserved Class 1A DHODHs (Fig. S2). <br />                                             These residues described pyrimidine binding motif: EZNLSCPNZPUKZQXXYD, <br />                                             U polar uncharged residue, X non-specific residue Z hydrophobic <br />                                             residue. <br />  <br />                                             A structure-based sequence alignment T. brucei, L. lactis 1B, human DHODHs, <br />                                             representing Classes 1A, 1B 2, respectively, shows Class 1 sequences an <br />                                             insertion 15 residues (residues 202&#8211;216) relative human Class 2 sequence (Figure 3). <br />                                             These residues form strand-loop-strand-loop (&#946;14-loop-&#946;15-loop) structural unit. Residues <br />                                             195&#8211;203 preceding insertion conserved Class 1A DHODHs form a <br />                                             NSXGNGLXI motif (1A motif 1) close proximity active site. Asn195 four <br />                                             conserved Asn residues interact orotate. <br />  <br />                                             The orotate binding site flanked loop consisting residues 132&#8211;138 (Fig. S4). This <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             loop highly conserved Class 1A DHODHs (Fig. S2). In crystal structures human <br />                                             DHODH corresponding loop poorly ordered, loop flexibility hypothesized allow <br />                                             active site open dihydroorotate enter orotate exit (Liu et al., 2000). <br />                                             In contrast human structure, loop present TbDHODH structure relatively <br />                                             closed conformation defined electron density. Nevertheless, orotate FMN <br />                                             binding sites accessible TbDHODH human structure absence <br />                                             N-terminal domain characteristic Class 2 DHODH (Figure 2). This difference in <br />                                             accessibility contribute differential sensitivity Class 1A Class 2 enzymes <br />                                             orotate analogues hydroxybenzoate. <br />  <br />                               RNA interference studies T. brucei DHODH <br />                                             Gene expression knockdown T. brucei DHODH achieved over-expressing a <br />                                             stem-loop RNA target gene bloodstream form T. brucei. Messenger RNA levels were <br />                                             decreased 95% 72 hours following induction RNA interference construct the <br />                                             addition tetracycline (Figure 4a). Knockdown T. brucei DHODH protein appeared be <br />                                             similarly substantial observed Western blots. This monitored seven days, with <br />                                             protein levels detected &lt;5% levels observed RNAi induction (Figure 4b). When <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             T. brucei cells grown standard medium (HMI-9), growth rates cells RNAi <br />                                             turned (TCN+) turned (TCN&#8722;) comparable (Figure 5a). The growth rates <br />                                             cultures virtually the control cells (&#8217;single-marker&#8217;) containing only <br />                                             T7 RNA polymerase Tet repressor genes maintained neomycin marker. The <br />                                             surprising observation normal cell growth led investigate parasites surviving <br />                                             scavenging pyrimidines medium. Note HMI-9 medium includes 16 &#181;M <br />                                             thymidine. When additional thymidine omitted medium, saw no <br />                                             change growth phenotype induction RNA interference DHODH (data <br />                                             shown). Since standard medium 10% fetal bovine serum, repeated <br />                                             experiment using commercially available dialyzed serum, depleted small <br />                                             molecules pyrimidines. Under conditions observed reduced growth upon <br />                                             induction RNAi construct. By day 4 growth rate significantly reduced was <br />                                             arrested day 6 (Figure 5b). Most cells expressing RNAi construct the <br />                                             pyrimidine-depleted medium took bloated, balloon-shaped morphology day 5. There <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 May 27. <br />                             Arakaki et al.                                                                                                 Page 5 <br />  <br />  <br />                                             small degree growth suppression TCN&#8722; cells compared single-marker <br />                                             controls, leaky expression RNAi construct. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             We proceeded test RNAi knockdown DHODH impair growth <br />                                             standard medium inhibitor pyrimidine uptake present. 5-fluorouracil (5- <br />                                             FU) tested shown potent inhibitor pyrimidine uptake T. <br />                                             brucei (Gudin et al., 2006). The inhibitory concentration 5-FU causing 50% growth <br />                                             inhibition (IC50) shifted 16-fold lower parasites undergoing knockdown DHODH <br />                                             (IC50 = 0.64 &#181;M) compared parasites undergoing knockdown (IC50 = 10.4 &#181;M) using <br />                                             standard medium (Figure 6). In follow finding, tested uptake 3H-5-FU into <br />                                             DNA T. brucei cells observed uptake 2-fold higher the <br />                                             DHODH-knockdown parasites controls (Figure 7). <br />  <br />                               Classification TbDHODH Class 1A inhibition hydroxybenzoates <br />                                             TbDHODH activity examined presence standard DHODH terminal <br />                                             electron acceptors (Figure 8) catalyze fumarate efficiently, typical of <br />                                             Family 1A enzymes (Andersen et al., 1994). The enzyme catalyzes reduction menadione <br />                                             (vitamin K3) ~20% rate fumarate catalysis, does appear perform electron <br />                                             transfer menaquinone (vitamin K2), ubiquinone analogues Q0, Q1, Q2, QD, to <br />                                             NAD+, characteristics Family 1A DHODH enzyme (Nara et al., 2000;Nielsen, <br />                                             Andersen Jensen, 1996;Marcinkeviciene et al., 2000). Catalysis DHO fumarate <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             displays saturation kinetics Km values 14 &#181;M DHO 80 &#181;M fumarate a <br />                                             Vmax 8.5 s&#8722;1 (Figure 9). The pH dependence enzyme activity assayed (Figure 9 inset) <br />                                             peak activity occur pH 7.8, indicative ionizable groups pKa <br />                                             values 6.3 9.2 involved substrate binding catalysis. Analysis TbDHODH <br />                                             activity range DHO fumarate concentrations produces double-reciprocal plot <br />                                             parallel lines (Figure 10), indicative ping-pong mechanism consistent results <br />                                             Family 1A enzymes (Marcinkeviciene et al., 2000). <br />  <br />                                             Inhibition TbDHODH benzoate pyrimidine analogues initially performed 1 <br />                                             mM inhibitor (data shown). Of benzoate pyrimidine analogues tested, 3,4- and <br />                                             3,5-dihydroxybenzoate displayed inhibition 1 mM concentration. Subsequent analysis of <br />                                             TbD-HODH inhibition 3,4- 3,5-dihydroxybenzoate various inhibitor DHO <br />                                             concentrations (Figure 11) revealed competitive inhibition 3,4-dihydroxybenzoate a <br />                                             Ki ~58 &#181;M (determined IC50 re-plot, shown) weaker inhibition 3,5- <br />                                             dihydroxybenzoate, appeared non-competitive yielded Ki 200 &#181;M. These values <br />                                             comparable reported Class 1A DHODHs (Feliciano et al., 2006; Takashima <br />                                             et al., 2002). <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               DISCUSSION <br />                               Divergent pyrimidine requirement T. cruzi T. brucei <br />                                             The Trypanosoma brucei genome contains enzymes required novo pyrimidine <br />                                             biosynthesis, indicating T. brucei capable providing pyrimidine pools <br />                                             (Berriman, 2004). The fourth enzyme pathway, DHODH, considered potential <br />                                             drug target parasitic protozoa including P. falciparum T. cruzi (McRobert and <br />                                             McConkey, 2002; Annoura et al., 2005; Baldwin et al., 2005). In particular, Class 1A <br />                                             DHODH T. cruzi shown gene disruption experiments necessary for <br />                                             growth epimastigotes (Annoura et al., 2005). We performed functional, enzymatic, and <br />                                             structural studies protein related parasite T. brucei, causative agent African <br />                                             sleeping sickness, attempt confirm similar essentiality. <br />  <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 May 27. <br />                             Arakaki et al.                                                                                                Page 6 <br />  <br />  <br />                                             Functional studies using RNA interference block TbDHODH revealed bloodstream T. <br />                                             brucei able grow normally enzyme, apparently scavenging pyrimidines <br />                                             medium (Figure 5). This ability scavenge pyrimidines entirely unexpected, <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             shown T. brucei surface transporters capable importing uracil and <br />                                             cytosine (de Koning Jarvis, 1998;Papageorgiou et al., 2005;Gudin et al., 2006). In addition, <br />                                             T. brucei genome contains enzymes associated pyrimidine salvage, <br />                                             including cytidine deam-inase (GeneDB Tb09.160.1680), uracil phosphoribosyltransferase <br />                                             (GeneDB Tb927.4.3320), thymidine kinase (GeneDB Tb10.70.7270). <br />  <br />                                             Thus, T. brucei, chemotherapeutic strategy deprive cells pyrimidine pools would <br />                                             appear require inhibition pyrimidine biosynthesis pyrimidine uptake/salvage. <br />                                             We tested feasibility two-pronged attack repeating DHODH RNAi <br />                                             knockdown experiments presence 5-FU, compound previously demonstrated to <br />                                             inhibit pyrimidine uptake T. brucei (Gudin et al., 2006). 5-FU itself cytotoxic high <br />                                             concentrations inhibition thymidylate synthase incorporation DNA RNA <br />                                             (de Bono Twelves, 2001). We observed cells undergoing dual treatment were <br />                                             affected DHODH knockdown, 16-fold sensitive 5-FU control <br />                                             cells (Figure 6). This suggests cells tolerate inhibition pyrimidine <br />                                             synthesis inhibition pyrimidine uptake. <br />  <br />                                             Although 5-FU inhibits pyrimidine uptake T. brucei, itself transported cells with <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             relatively high efficiency (Gudin et al., 2006). A possible cellular response suppression <br />                                             pyrimidine biosynthesis, case interference DHODH, up-regulate <br />                                             import pathway. Thus follow-up experiment performed determine relative <br />                                             uptake radiolabelled 5-FU DNA T. brucei cells presence absence of <br />                                             DHODH suppression. The experiment demonstrated &gt;2x higher 5-FU incorporation into <br />                                             DHODH knockdown cells controls (Figure 7). It likely increased <br />                                             incorporation 5-FU DNA partly account enhanced sensitivity drug. <br />                                             We speculate increased incorporation 5-FU DNA DHODH knockdown <br />                                             cells results following factors: 1) depletion intracellular <br />                                             pyrimidine pools favors incorporation 5-FU, 2) possible up-regulation enzymes <br />                                             convert 5-FU 5-fluorouracil monophosphate (FUMP), 5-fluorouracil diphosphate <br />                                             (FUDP), 5-fluorouracil triphosphate (FUTP), 3) possible increased uptake 5-FU due <br />                                             up-regulated pyrimidine transporter activity cell surface. Future experiments be <br />                                             necessary better establish mechanisms responsible observations. <br />  <br />                                             Whichever mechanisms play, apparent synergy DHODH <br />                                             knockdown plus 5-FU treatment significant implications pursuing pyrimidine <br />                                             biosynthesis pathway drug target T. brucei. One imagine combination treatment <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             including 5-FU new compound specifically inhibits T. brucei DHODH (or <br />                                             possibly enzyme pyrimidine biosynthesis pathway). A new DHODH inhibitor <br />                                             &#8220;chemosensitizer&#65533;? 5-FU dramatically enhance activity 5- <br />                                             FU treating T. brucei infection. 5-FU established clinical drug use <br />                                             1950&#8217;s. It known toxicities, certainly advantages existing <br />                                             human African trypanosomiasis drugs (e.g. melarso-prol, suramin, pentamidine, etc.) are <br />                                             extremely toxic require parenteral administration. It important develop partner <br />                                             drug inhibits T. brucei DHODH selectively. Since human DHODH Class 2 <br />                                             enzyme functionally structurally distinct Class 1 T. brucei enzyme, we <br />                                             expect finding selective inhibitors quite feasible. The data presented provide a <br />                                             strong rationale pursuing research T. brucei DHODH <span id='am-125' about='obo:NCBITaxon_order' typeof='owl:Thing NCBITaxon:_taxonomic_rank'><span id='am-126' property="rdfs:label" content="order" datatype="xsd:string"></span><span id='am-127' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>order</span> develop <br />                                             potent inhibitors drug leads. <br />  <br />  <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 May 27. <br />                             Arakaki et al.                                                                                               Page 7 <br />  <br />  <br />                               Inhibitors trypanosomal Class 1A DHODH <br />                                             The previous focus inhibitor studies largely directed Class 2 DHODHs. The P. <br />                                             falciparum enzyme (PfDHODH) focus significant potential new <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             target development anti-malarials (Baldwin et al., 2005), human enzyme is <br />                                             targeted treatment <span id='am-104' about='obo:NCBITaxon_6754' typeof='owl:Thing obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_72041 obo:NCBITaxon_33154 obo:NCBITaxon_6681 obo:NCBITaxon_6682 obo:NCBITaxon_6683 obo:NCBITaxon_29964 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_33208 obo:NCBITaxon_116706 obo:NCBITaxon_116704 obo:NCBITaxon_197562 obo:NCBITaxon_197563 obo:NCBITaxon_6656 obo:NCBITaxon_6692 obo:NCBITaxon_1206794 obo:NCBITaxon_6657 obo:NCBITaxon_6753 obo:NCBITaxon_88770 obo:NCBITaxon_6752'><span id='am-105' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-106' property="rdfs:label" content="Cancer" datatype="xsd:string"></span><span id='am-107'  ></span><span id='am-108' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>cancer</span>, gastric ulcers, rheumatoid arthritis (Palfey et al., 2001). <br />                                             Structural studies PfDHODH inhibitors based brequinar analogues (<span id='am-117' about='obo:NCBITaxon_8573' typeof='owl:Thing obo:NCBITaxon_1329950 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_32523 obo:NCBITaxon_131567 obo:NCBITaxon_32524 obo:NCBITaxon_117570 obo:NCBITaxon_89593 obo:NCBITaxon_7742 obo:NCBITaxon_117571 obo:NCBITaxon_33154 obo:NCBITaxon_196244 obo:NCBITaxon_8504 obo:NCBITaxon_1338369 obo:NCBITaxon_8287 obo:NCBITaxon_8509 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_33511 obo:NCBITaxon_1329912 obo:NCBITaxon_33208 obo:NCBITaxon_1329961 obo:NCBITaxon_1329911 obo:NCBITaxon_7711 obo:NCBITaxon_8572 obo:NCBITaxon_8570 obo:NCBITaxon_34979 obo:NCBITaxon_7776 obo:NCBITaxon_32561 obo:NCBITaxon_8457'><span id='am-118'  ></span><span id='am-119' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-120' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-121' property="rdfs:label" content="Boa" datatype="xsd:string"></span>Boa</span> et al., 2005), <br />                                             biphenylamides (Baldwin et al., 2005), A771726 (Heikkil&#228; et al., 2006), atovaquone (Hansen <br />                                             et al., 2004), lefluno-mide (Hurt et al., 2006) analogues bind similarly, <br />                                             attacking ubiquinone binding site formed jointly N- C-terminal domains (Figure <br />                                             2c). Unfortunately, given involvement Class 2-specific N-terminal domain, class <br />                                             inhibitors unlikely relevant Class 1 enzymes. <br />  <br />                                             However, inhibitors specific Class 1A enzymes known, including <br />                                             hydroxybenzoates. These orotate analogs shown specifically inhibit the <br />                                             L. lactis Class 1A DHODH minimal effect L. lactis Class 1B enzyme human <br />                                             E. coli Class 2 enzymes (Palfey et al., 2001). Although stereochemistry protein <br />                                             residues forming orotate binding site Class 1A Class 2 enzymes nearly identical, <br />                                             redox mechanism differs classes (Fagan et al., 2007). Fagan et al. (2007) have <br />                                             attributed subtle dynamic features proteins. On basis present structure, <br />                                             suggest features include differential access orotate FMN sites the <br />                                             &quot;front&quot; protein (Figure 2) difference relative mobility observed <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             crystallographically residues 132&#8211;138 pyr-binding motif (Figure 3). <br />  <br />                                             Wolfe et al. (2007) investigated structural details kinetics hydroxybenzoate <br />                                             inhibition L. lactis Class 1A DHODH. The inhibitor observed crystallographically <br />                                             monomer homodimer, consistent kinetic data showing cooperativity <br />                                             monomers dimer. The structural basis cooperativity not <br />                                             evident (Wolfe et al., 2007). Given high structural conservation L. lactis <br />                                             structure present T. brucei structure, plausible class inhibitors <br />                                             relevant trypanosomal homologs. We shown inhibition assays <br />                                             TbDHODH hydroxybenzoate inhibitors act bacterial DHODHs but <br />                                             Class 1A DHODH eukaryotic parasite. In particular, competitive <br />                                             inhibition 3,4-dihydroxybenzoate (Ki 58 &#181;M) non-competitive inhibition 3,5- <br />                                             dihydroxybenzoate (Ki 200 &#181;M). These Ki values higher reported L. <br />                                             lactis remain possible starting points anti-parasitic drug design. <br />  <br />                               Applicability inhibitor design pathogens <br />                                             T. brucei representative larger class pathogenic protozoan parasites responsible for <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             substantial burden human disease. In evaluating importance TbDHODH possible <br />                                             drug target, drugs acting TbDHODH be <br />                                             effective related pathogens. Class 1A DHODHs primarily bacterial, they <br />                                             acquired yeasts (<span id='am-58' about='obo:NCBITaxon_4930' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_4751 obo:NCBITaxon_4893 obo:NCBITaxon_33154 obo:NCBITaxon_451864 obo:NCBITaxon_4892 obo:NCBITaxon_4891 obo:NCBITaxon_4890 obo:NCBITaxon_716545 obo:NCBITaxon_2759 obo:NCBITaxon_147537'><span id='am-59' property="rdfs:label" content="Saccharomyces" datatype="xsd:string"></span><span id='am-60' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-61'  ></span><span id='am-62' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-63' property="oboInOwl:hasRelatedSynonym" content="Pachytichospora" datatype="xsd:string"></span><span id='am-64' property="oboInOwl:hasAlternativeId" content="NCBITaxon:36915" datatype="xsd:string"></span>Saccharomyces</span>, <span id='am-53' about='obo:NCBITaxon_4910' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_4751 obo:NCBITaxon_4893 obo:NCBITaxon_33154 obo:NCBITaxon_451864 obo:NCBITaxon_4892 obo:NCBITaxon_4891 obo:NCBITaxon_4890 obo:NCBITaxon_716545 obo:NCBITaxon_2759 obo:NCBITaxon_147537'><span id='am-54' property="rdfs:label" content="Kluyveromyces" datatype="xsd:string"></span><span id='am-55' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-56'  ></span><span id='am-57' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>Kluyveromyces</span>) apparently through <br />                                             lateral gene transfer <span id='am-15' about='obo:NCBITaxon_1357' typeof='obo:NCBITaxon_91061 owl:Thing obo:NCBITaxon_1239 obo:NCBITaxon_1 obo:NCBITaxon_1300 obo:NCBITaxon_131567 obo:NCBITaxon_2 obo:NCBITaxon_186826'><span id='am-16' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-17' property="oboInOwl:hasDbXref" content="GC_ID:11" datatype="xsd:string"></span><span id='am-18' property="rdfs:label" content="Lactococcus" datatype="xsd:string"></span><span id='am-19'  ></span><span id='am-20' property="oboInOwl:hasExactSynonym" content="lactic streptococci" datatype="xsd:string"></span>Lactococcus</span> (Hall et al., 2005). The appearance Class 1A DHODH <br />                                             trypanosomatids similarly lateral transfer, point introduction <br />                                             clade protozoan lineages known. <br />  <br />                                             The sequences T. brucei Class 1A, L. lactis Class 1B, P. falciparum Class 2 DHODH <br />                                             submitted GeneDB omni-BLAST server (Hertz-Fowler et al., 2004) find <br />                                             homologs protozoa. No species contain DHODH class. <br />                                             No protozoan Class 1B homologs detected. The <span id='am-92' about='obo:NCBITaxon_5820' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_5794 obo:NCBITaxon_131567 obo:NCBITaxon_422676 obo:NCBITaxon_2759 obo:NCBITaxon_5819 obo:NCBITaxon_33630'><span id='am-93'  ></span><span id='am-94' property="rdfs:label" content="Plasmodium" datatype="xsd:string"></span><span id='am-95' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-96' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>Plasmodium</span> genomes contain Class <br />                                             2 sequences. The sequences T. brucei, T.b. gambiense, T. cruzi, T. congolense, T. vivax, <br />                                             L. major, L. infantum &gt;75% sequence identity genome strain TbDHODH. The <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 May 27. <br />                             Arakaki et al.                                                                                             Page 8 <br />  <br />  <br />                                             residues involved binding FMN orotate conserved, suggesting drug design based <br />                                             TbDHODH structure relevant pathogenic trypanosomatids. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               Summary <br />                                             We shown RNAi interference dihydroorotate dehydrogenase bloodstream <br />                                             form Trypanosoma brucei inhibits growth access pyrimidines environment is <br />                                             blocked. This calls question general essentiality pyrimidine biosynthesis <br />                                             pathway T. brucei, distinction previous report essentiality T. cruzi. However, <br />                                             shown RNAi suppression DHODH synergistic effect the <br />                                             complementary growth-blocking agent 5-FU, inhibits pyrimidine uptake. This <br />                                             demonstrates interference T. brucei DHODH potentiate activity the <br />                                             established clinical drug 5-FU bloodstream form T. brucei. <br />  <br />                                             The crystal structure enzymatic properties T. brucei enzyme active site <br />                                             similar Class 1A DHODHs Class 2 DHODHs higher <br />                                             eukaryotes, including human DHODH. Encouragingly, inhibited hydroxybenzoates, in <br />                                             common Class 1A DHODHs distinction Class 2 human DHODH. <br />  <br />                                             Thus T. brucei DHODH, extension enzymes pyrimidine biosynthetic <br />                                             pathway, remains possible target development two-pronged therapeutic approach <br />                                             attacking pyrimidine biosynthesis pyrimidine uptake. Furthermore, propose that <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             molecular details provided present TbDHODH structure useful designing <br />                                             selective inhibitors potential lead compounds targeting protozoan dihydroorotate <br />                                             dehydrogenases. <br />  <br />                               MATERIALS AND METHODS <br />                               Protein expression crystallography <br />                                             The gene encoding TbDHODH PCR amplified genomic DNA strain T. <br />                                             brucei TREU927 GUTat 10.1 cloned vector AVA421, based E. coli <br />                                             expression vector pET14b (Alexandrov et al., 2004). The AVA421 vector contains cleavable <br />                                             N-terminal His-tag. The protein purified using Ni-NTA column bound protein <br />                                             cleaved protease 3C overnight 4&#176;C. The released protein purified gel <br />                                             filtration HiLoad Superdex 200. <br />  <br />                               Protein expression enzymatic studies <br />                                             The DHODH gene amplified T. brucei brucei 427 strain genomic DNA by <br />                                             polymerase chain reaction using primers 5&#8217;- <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             CGCAAAGGGAAAAGTCATATGAGTTTGAAAGTTAAT-3&#8217; 5&#8217;- <br />                                             CATCAACACCCATGTATCTCGAGATCCATCGTCTTCACGC-3&#8217;, introduced <br />                                             NdeI XhoI restriction sites. The product subcloned, ligated pET22b (EMD <br />                                             Biosciences) providing C-terminus His tag. The resulting TbDHODH-pET22b plasmid was <br />                                             transformed BL21-DE3 E. coli cells, grown LB-Miller medium and <br />                                             OD600nm 0.8, supplemented 100 &#181;M FMN induced 200 &#181;M IPTG. A <br />                                             cell pellet collected 3 hours induction resuspended lysis buffer (50 mM sodium <br />                                             phosphate, pH 8.0, 10 mM imidazole, 5 mM 2-mercaptoethanol, 10% glycerol, 1 mg/ml <br />                                             lysozyme, 0.1 mg/ml DNAse) protease inhibitor cocktail added final <br />                                             concentration 200 &#181;M phenylmethylsulfonyl fluoride, 1 &#181;g/ml leupeptin, 2 &#181;g/ml antipain, <br />                                             10 &#181;g/ml benzamidine, 1 &#181;g/ml pepstatin 1 &#181;g/ml chymostatin. The lysis mixture then <br />                                             incubated 2 hours ice constant stirring, sonicated centrifuged 20,000 &#215; g for <br />                                             30 minutes 4&#176;C. The supernatant centrifugation loaded 10 ml column of <br />                                             nickel agarose resin (Qiagen) equilibrated Wash Buffer (50 mM sodium phosphate, pH <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 May 27. <br />                             Arakaki et al.                                                                                              Page 9 <br />  <br />  <br />                                             8.0, 300 mM sodium chloride, 20 mM imidazole, 5 mM 2-mercaptoethanol, 10% glycerol). <br />                                             The column washed volumes Wash Buffer, His6-tagged protein eluted <br />                                             Elution Buffer (50 mM sodium phosphate, pH 8.0, 300 mM sodium chloride, 300 mM <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             imidazole, 5 mM 2-mercaptoethanol, 10% glycerol). The eluted protein pooled and <br />                                             concentrated 2 ml Centriprep YM-10 centrifugal filtration device (Amicon <br />                                             Millipore) applied HiPrep 26/10 Desalting Column (Amersham Biosciences) <br />                                             equilibrated 50 mM sodium phosphate, pH 8.0, 150 mM sodium chloride, 10% <br />                                             glycerol. Protein containing fractions pooled concentrated above. <br />  <br />                               Crystallization <br />                                             Purified TbDHODH shipped dry ice High Throughput Crystallization Screening at <br />                                             Hauptman-Woodward Medical Research Institute (Luft et al., 2003). The sample was <br />                                             rapidly thawed 30&#176;C water bath orotic acid (8 &#181;l 200mM orotic acid stock solution) <br />                                             added 392 &#181;l protein solution. Crystallization experiments set using the <br />                                             microbatch-under-oil technique (Chayen et al., 1992) Robbins Scientific Tango liquid <br />                                             handling system. Each 1536 experiments contained 200 nl crystallization cocktail <br />                                             solution combined 200 nl protein solution USP grade mineral oil (Sigma cat <br />                                             #M1180) contained low birefringence 1536 microassay plate (Greiner BioOne cat# <br />                                             790801). Manual review plate images 1 week 4&#176;C identified 124 crystallization <br />                                             conditions outcomes considered suitable optimization trials. Eight initial hits were <br />                                             optimized crystals grown sitting drop method. Crystals used data collection grew <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             drop consisting 0.4 &#181;l protein solution (14.1 mg/ml), mixed 0.4 &#181;l reservoir <br />                                             solution containing 40% PEG 1000, 0.1M Na citrate, 0.1M KBr, pH 4.0 room temperature. <br />  <br />                               X-ray crystal structure determination structural analysis <br />                                             Native crystals flash frozen directly liquid nitrogen. Data collected 1.95&#197; <br />                                             resolution single crystal maintained 100K, X-ray wavelength corresponding to <br />                                             bromine K edge (&#955; = 0.92010&#197;), ALS beamline 8.2.1. Data processed scaled <br />                                             using MOSFLM CCP4 program package (Collaborative Computational Project No. 4, <br />                                             1994) automated Wedger Scaler scripts Elves (Holton Alber, 2004). Data <br />                                             processing statistics shown Table 1. The contribution anomalous dispersion from <br />                                             ordered Br atoms measured Bragg intensities insufficient solve structure using <br />                                             SAD phasing, 11 partially-occupied sites later identified refined structure. <br />                                             Therefore structure L. lactis DHODH (PDB accession code 1jue, 51% sequence identity) <br />                                             submitted Swiss-model server (Guex Peitsch, 1997; Schwede et al., 2003) to <br />                                             create <span id='am-182' about='obo:NCBITaxon_37965' typeof='owl:Thing obo:NCBITaxon_12908 obo:NCBITaxon_1'><span id='am-183'  ></span><span id='am-184' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-185' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-186' property="rdfs:label" content="hybrid" datatype="xsd:string"></span>hybrid</span> homology model based structure L. lactis DHODH containing <br />                                             TbDHODH residues. This model submitted Molrep (Vagin Teplyakov, 1997), <br />                                             placed copies monomeric model a.s.u. yielding correlation <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             coefficient 0.60. The TbDHODH structure refined using Refmac5 (Murshudov et al., <br />                                             1997) reflections 21 &#197; 1.95 &#197; resolution, keeping 5% reflections <br />                                             Rf ree. Model building validation accomplished using Coot (Emsley Cowtan, <br />                                             2004) Molprobity (Lovell et al., 2003). Electron density region orotate binding <br />                                             site shown Fig. S5. The final model consists molecules forming dimers. The <br />                                             final model monomer consists residues 1&#8211;313, orotate, FMN molecule. <br />                                             The overall model contains 11 bromide atoms, 3 glycerol molecules 638 water <br />                                             molecules. The final model crystallographic structure factors deposited the <br />                                             Protein Data Bank (accession code 2b4g). <br />  <br />                               Enzyme kinetic inhibition assays <br />                                             Enzyme kinetic assays performed enzyme assay buffer (50 mM HEPES, pH 8.0, 150 <br />                                             mM NaCl, 10% glycerol) 25&#176;C. Analysis pH dependence utilized MES (pH 5.5&#8211;6.5), <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 May 27. <br />                             Arakaki et al.                                                                                           Page 10 <br />  <br />  <br />                                             <span id='am-177' about='obo:NCBITaxon_258862' typeof='owl:Thing obo:NCBITaxon_9397 obo:NCBITaxon_9436 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_32523 obo:NCBITaxon_131567 obo:NCBITaxon_117570 obo:NCBITaxon_32524 obo:NCBITaxon_32525 obo:NCBITaxon_89593 obo:NCBITaxon_7742 obo:NCBITaxon_117571 obo:NCBITaxon_33154 obo:NCBITaxon_1437010 obo:NCBITaxon_1338369 obo:NCBITaxon_40674 obo:NCBITaxon_8287 obo:NCBITaxon_314145 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_33511 obo:NCBITaxon_33208 obo:NCBITaxon_7711 obo:NCBITaxon_30560 obo:NCBITaxon_7776 obo:NCBITaxon_9347'><span id='am-178' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-179'  ></span><span id='am-180' property="rdfs:label" content="Mops" datatype="xsd:string"></span><span id='am-181' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>MOPS</span> (6.5&#8211;7.5), Tris (7.5&#8211;9.0), CHES (9.0&#8211;10.0) buffer salts place HEPES. <br />                                             Production orotate monitored 300 nm (&#949;300 = 2.65 mM&#8722;1cm&#8722;1) using fumarate, <br />                                             282 nm (&#949;282 = 6.60 mM&#8722;1cm&#8722;1) using vitamin K analogues, 296 nm (&#949;296 = <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             4.30 mM&#8722;1cm&#8722;1) using ubiquinone analogues. Reduction NAD+ monitored at <br />                                             340 nm (&#949;340 = 6.22 mM&#8722;1cm&#8722;1). Strong absorption far-UV inhibitors tested <br />                                             required use traditional electron acceptor dichlorophenolindophenol (DCIP) in <br />                                             inhibition studies reduction DCIP followed 600 nm (&#949;600 = 18.8 <br />                                             mM&#8722;1cm&#8722;1). <br />  <br />                                             DHO-dependent activity examined presence 500 &#181;M fumarate. Fumarate- <br />                                             dependent activity assayed constant DHO concentration 250 &#181;M. Data were <br />                                             analyzed using software package GraphPad Prism SigmaPlot fitted the <br />                                             Michaelis-Menten equation. <br />  <br />                                             Alternative electron acceptors (vitamin K ubiquinone analogues, NAD+) assayed at <br />                                             100 &#181;M electron acceptor (dissolved oxygen estimated ~210 &#181;M) 250 &#181;M DHO. <br />                                             Inhibitors initially examined 1 mM presence 25 &#181;M DHO 120 &#181;M DCIP, <br />                                             subsequent assays utilized 120 &#181;M DCIP various DHO inhibitor concentrations. <br />                                             All experiments performed duplicate; combined data presented, kinetic <br />                                             parameters reported mean &#177; standard error fit. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               Analytical ultracentrifugation <br />                                             Analytical ultracentrifugation performed Beckman XL-I analytical ultracentrifuge <br />                                             enzyme observed 280 nm (protein) 454 nm (FMN). Enzyme samples 5&#8211;25 <br />                                             &#181;M centrifuged 14000 20000 rpm 4&#176;C, equilibrium sedimentation scans were <br />                                             obtained hours, equilibrium determined reached contiguous <br />                                             scans indistinguishable. Data fitted single ideal species model a <br />                                             monomer-dimer model representative result multiple experiments presented. <br />  <br />                               RNA interference <br />                                             A region TbDHODH gene sequence selected RNAi using program RNAit <br />                                             (Redmond et al., 2003). Bases 413&#8211;859 gene amplified T. brucei 927 genomic <br />                                             DNA using primers 5&#8217;-ATACCAATGTGATGGCACAGGTCGGATATGACTTTGA-3&#8217; <br />                                             5&#8217;-ATACCATAGAGTTGGGTTGAGTCGAGCAAATATGATG-3&#8217;. The amplicon was <br />                                             ligated using TA cloning vector pGEM-T (Promega, cat# A3600), excised with <br />                                             enzyme BstXI. This insert ligated stem-loop RNAi vector, pQuadra3, as <br />                                             described (Inoue et al., 2005). The construct sequenced verify identity of <br />                                             insert, linearized NotI preparation electroporation. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             T. brucei bloodstream-form parasites expressing T7 RNA polymerase Tet repressor <br />                                             single selection marker provided G. Cross (Rockefeller University) (Wirtz et <br />                                             al., 1999). The cells grown HMI-9 10% heat-inactivated fetal bovine serum at <br />                                             37&#176;C 5% CO2 G418 2.5 &#181;g/ml (Hirumi Hirumi, 1989). Mid-log phase T. <br />                                             brucei (2.5 &#215; 107) suspended 500 &#181;l cytomix (120mM KCl, 0.15 mM CaCl2, 10 <br />                                             mM K2HPO4/KH2PO4 pH 7.6, 25 mM Hepes, 2 mM Na2EDTA, 5 mM MgCl2) containing <br />                                             10 &#181;g NotI linearized pQuadra3/DHODH DNA. The mixture electroporated 4mm <br />                                             gap cuvette 1.6 kV 24&#8486; resistance. Cells re-suspended HMI-9 medium the <br />                                             presence 2.5 &#181;g/ml phleomycin 2.5 &#181;g/ml G418. Individual clones selected for <br />                                             subsequent RNAi studies. The expression dsRNA induced addition 1 &#181;g/ml <br />                                             tetracycline cultures diluted 1 &#215; 105 cells/ml. Cultures passed 1:10&#8211;1:20 <br />                                             dilution daily cell concentrations monitored using ATPLite Luminescence ATP <br />                                             detection Assay System (PerkinElmer, cat #6016941). <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 May 27. <br />                             Arakaki et al.                                                                                            Page 11 <br />  <br />  <br />                                             Separate growth experiments performed using HMI-9 medium omitted thymidine <br />                                             (normally included 16 &#181;M). There pyrimidine bases medium; is <br />                                             supplemented 100 &#181;M hypoxanthine source purines. The medium was <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             supplemented 10% dialyzed fetal bovine serum (Hyclone) complete pyrimidine <br />                                             depleted medium. <br />  <br />                               Northern analysis <br />                                             RNA isolated induced non-induced cultures 72 h growth using RNEasy <br />                                             kit (Qiagen). 16 &#181;g total RNA electrophoresed formaldehyde gel blotted using <br />                                             standard procedures. The RNA membrane analyzed DNA probe amplified <br />                                             genomic DNA using primers 5&#8217;-CTCGGACATGAGTTTTCCAACC-3&#8217; 5&#8217;- <br />                                             GGCTTCCTACTGTAATCGTG 3&#8217; correspond bases 22&#8211;281 DHODH open <br />                                             reading frame. The blot stripped re-probed DNA T. brucei &#946;-tubulin gene <br />                                             standardization. <br />  <br />                               IC50 shift assay <br />                                             Sensitivity 5-FU tested trypomastigotes single marker parent line the <br />                                             single marker cells containing pQuadra3/DHODH RNAi vector uninduced cells <br />                                             cells induced 48 hours 1 &#181;g/ml tetracycline. Cells added 96-well plates <br />                                             triplicate initial inoculum 2 &#215; 104 trypomastigotes well. The compound stock <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             solution 5-fluorouracil (Sigma, F6627) prepared using sterile water initial <br />                                             concentration 20 mM. This diluted HMI-9 concentration 120 &#181;M added <br />                                             serial dilutions final volume 200ul/well. Parasite growth quantified 48 hours <br />                                             addition Alamar Blue (Alamar Biosciences, DAL1100) (Raz et al., 1997). <br />  <br />                               5-FU incorporation experiment <br />                                             Incorporation 5-FU T. brucei genomic DNA measured bloodstream forms <br />                                             single marker parent cell line bloodstream forms containing pQuadra3/ <br />                                             DHODH RNAi construct. Measurements taken uninduced cultures cultures <br />                                             induced 72 hours 1 &#181;g/ml tetracycline. The trypomastigotes all <br />                                             grown standard HMI-9 containing thymidine hypoxanthine, 2.5 &#181;g/ml <br />                                             neomycin. In addition, cells containing pQuadra3/DHODH RNAi vector also <br />                                             grown presence 2.5 &#181;g/ml phleomycin. After 72 hour induction, cells were <br />                                             transferred 96-well plate pulsed 5 &#181;Ci [6-3H]-5-FU (Moravek Biochemicals, <br />                                             MT-686) 24 hours. Cell density quantification, order standardize results, done <br />                                             30 ul sample using ATPLite Luminescence ATP detection Assay System <br />                                             (PerkinElmer, cat #6016941) described above. The incorporation 3H-5-FU measured <br />                                             binding DNA remaining 175 &#181;l glass fiber filters cell harvester <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             (Inotech Biosystems International, Inc., Rockville, MD), radioactivity incorporated <br />                                             parasites counted Chameleon 425-104 multilabel plate scintillation counter <br />                                             (Hidex Oy, Turku, Finland). <br />  <br />                               Antibody production Western immunoblotting <br />                                             Purified TbDHODH sent Affinity BioReagents (Golden, CO) antibody production <br />                                             rabbits previously described (www.bioreagents.com/index.cfm/fuseaction/content.aod). <br />                                             Antibody specificity confirmed purified TbDHODH T. brucei cells lysates <br />                                             using pre-immune post-challenge serum specific. The anti-TbDHODH <br />                                             antibodies used Western blots lysates T. brucei bloodstream form cells collected <br />                                             daily time intervals induction RNAi. Standard Western blot procedures <br />                                             followed using goat-horseradish peroxidase-conjugated secondary antibody ECL <br />                                             detection (Amersham Biosciences). Relative TbDHODH protein levels determined by <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 May 27. <br />                             Arakaki et al.                                                                                                             Page 12 <br />  <br />  <br />                                             densitometry. The numerical values normalized stained bands transferred <br />                                             SDS-PAGE gel (not shown). <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               Supplementary Material <br />                                             Refer Web version PubMed Central supplementary material. <br />  <br />  <br />                               Acknowledgments <br />                                             We thank Jonathan Caruthers Meg Holmes aid data collection. We reliant efforts other <br />                                             members SGPP consortium, including Eric Phizicky, Erin Quartley, <span id='am-128' about='obo:NCBITaxon_444773' typeof='owl:Thing obo:NCBITaxon_33340 obo:NCBITaxon_33208 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_85512 obo:NCBITaxon_197562 obo:NCBITaxon_197563 obo:NCBITaxon_33154 obo:NCBITaxon_6656 obo:NCBITaxon_267072 obo:NCBITaxon_7496 obo:NCBITaxon_1206794 obo:NCBITaxon_88770 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_7505 obo:NCBITaxon_6970 obo:NCBITaxon_7504 obo:NCBITaxon_33341 obo:NCBITaxon_50557 obo:NCBITaxon_6072 obo:NCBITaxon_6960'><span id='am-129' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-130' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-131'  ></span><span id='am-132' property="rdfs:label" content="Angela" datatype="xsd:string"></span>Angela</span> Lauricella, Lori Schoenfeld, <br />                                             Jennifer Ross, Frank Zucker, Thomas Earnest. We thank Dr. HP Koning helpful discussions T. <br />                                             brucei transporter activities. This work supported Protein Structure Initiative, award NIGMS GM64655; <br />                                             NIH award AI067921; funds Howard Hughes Medical Institute (HHMI) WGJH; National <br />                                             Institutes Health Grants AI053680 MAP. Portions work carried Advanced Light Source, <br />                                             supported Director, Office Science, Office Basic Energy Sciences, U.S. Department of <br />                                             Energy Contract No. DE-AC02-05CH11231. <br />  <br />  <br />                               REFERENCES <br />                                             Alexandrov A, Vignali M, LaCount DJ, Quartley E, Vries C, <span id='am-47' about='obo:NCBITaxon_3764' typeof='owl:Thing obo:NCBITaxon_78536 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_3745 obo:NCBITaxon_3398 obo:NCBITaxon_3744 obo:NCBITaxon_171638 obo:NCBITaxon_1437183 obo:NCBITaxon_33090 obo:NCBITaxon_91827 obo:NCBITaxon_131221 obo:NCBITaxon_71240 obo:NCBITaxon_1176516 obo:NCBITaxon_58024 obo:NCBITaxon_1437201 obo:NCBITaxon_58023 obo:NCBITaxon_91835 obo:NCBITaxon_2759 obo:NCBITaxon_35493 obo:NCBITaxon_71275 obo:NCBITaxon_3193'><span id='am-48' property="oboInOwl:hasRelatedSynonym" content="Rosa L." datatype="xsd:string"></span><span id='am-49' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-50'  ></span><span id='am-51' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-52' property="rdfs:label" content="Rosa" datatype="xsd:string"></span>Rosa</span> DD, Babulski J, Mitchell SF, <br />                                                Schoenfeld LW, Fields S, Hol WG, Dumont ME, Phizicky EM, Grayhack EJ. A facile method for <br />                                                high-throughput co-expression protein pairs. Mol Cell Proteomics 2004;3:934&#8211;938. [PubMed: <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                15240823] <br />                                             Andersen PS, Jansen PJ, Hammer K. Two different dihydroorotate dehydrogenases <span id='am-6' about='obo:NCBITaxon_1358' typeof='obo:NCBITaxon_91061 owl:Thing obo:NCBITaxon_1357 obo:NCBITaxon_1239 obo:NCBITaxon_1 obo:NCBITaxon_1300 obo:NCBITaxon_131567 obo:NCBITaxon_2 obo:NCBITaxon_186826'><span id='am-7' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-8' property="oboInOwl:hasRelatedSynonym" content="Streptococcus lactis" datatype="xsd:string"></span><span id='am-9' property="oboInOwl:hasRelatedSynonym" content="Bacterium lacti" datatype="xsd:string"></span><span id='am-10'  ></span><span id='am-11' property="oboInOwl:hasDbXref" content="GC_ID:11" datatype="xsd:string"></span><span id='am-12' property="oboInOwl:hasRelatedSynonym" content="Lactococcus lactis (Lohnis) Schleifer et al. 1986" datatype="xsd:string"></span><span id='am-13' property="rdfs:label" content="Lactococcus lactis" datatype="xsd:string"></span><span id='am-14' property="oboInOwl:hasDbXref" content="PMID:11594628" datatype="xsd:string"></span>Lactococcus lactis</span>. <br />                                                J Bacteriol 1994;176:3975&#8211;3982. [PubMed: 8021180] <br />                                             Annoura T, Nara T, Makiuchi T, Hashimoto T, Aoki T. The origin dihydroorotate dehydrogenase <br />                                                genes kinetoplastids, special reference biological significance adaptation to <br />                                                anaerobic, parasitic conditions. J Mol Evol 2005;60:113&#8211;127. [PubMed: 15696374] <br />                                             Baldwin J, Michnoff CH, Malmquist NA, White J, Roth MG, Rathod PK, Phillips MA. High-throughput <br />                                                screening potent selective inhibitors <span id='am-97' about='obo:NCBITaxon_5833' typeof='obo:NCBITaxon_5820 owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_5794 obo:NCBITaxon_131567 obo:NCBITaxon_418107 obo:NCBITaxon_422676 obo:NCBITaxon_2759 obo:NCBITaxon_5819 obo:NCBITaxon_33630'><span id='am-98' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-99' property="oboInOwl:hasExactSynonym" content="malaria parasite P. falciparum" datatype="xsd:string"></span><span id='am-100'  ></span><span id='am-101' property="oboInOwl:hasRelatedSynonym" content="Plasmodium (Laverania) falciparum" datatype="xsd:string"></span><span id='am-102' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-103' property="rdfs:label" content="Plasmodium falciparum" datatype="xsd:string"></span>Plasmodium falciparum</span> dihy-droorotate <br />                                                dehydrogenase. J Biol Chem 2005;280:21847&#8211;21853. [PubMed: 15795226] <br />                                             Beitz E. TEXshade: shading labeling multiple sequence alignments using LATEX2 epsilon. <br />                                                Bioinformatics 2000;16:135&#8211;139. [PubMed: 10842735] <br />                                             Berriman M. Data mining parasite genomes. Parasitology 2004;(128 Suppl):S23&#8211;S31. [PubMed: <br />                                                16454895] <br />                                             Boa AN, Canavan SP, Hirst PR, Ramsey C, Stead AMW, McConkey GA. Synthesis brequinar analogue <br />                                                inhibitors malaria parasite dihydroorotate dehydrogenase. Bioorg Med Chem 2005;13:1945&#8211;1967. <br />                                                [PubMed: 15727850] <br />                                             Chaudhary K, Roos DS. Protozoan genomics drug discovery. Nat Biotechnol 2005;23:1089&#8211;1091. <br />                                                [PubMed: 16151400] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Chayen NE, Stewart PDS, Blow DM. Microbatch crystallization oil &#8211; new technique allowing <br />                                                small-volume crystallization trials. Journal Crystal Growth 1992;122:176&#8211;180. <br />                                             Collaborative Computational Project No. 4. The ccp4 suite: programs protein crystallography. Acta <br />                                                  Cryst 1994;D50:760&#8211;763. <br />                                             Bono JS, Twelves CJ. The oral fluorinated pyrimidines. Invest New Drugs 2001;19(1):41&#8211;59. <br />                                                  [PubMed: 11291832] <br />                                             Koning HP, Jarvis SM. A highly selective, high-affinity transporter uracil Trypanosoma brucei <br />                                                  brucei: evidence proton-dependent transport. Biochem Cell Biol 1998;76:853&#8211;858. [PubMed: <br />                                                  10353720] <br />                                             Emsley P, Cowtan K. Coot: model-building tools molecular graphics. Acta Cryst 2004;D60:2126&#8211; <br />                                                  2132. <br />                                             Fagan R, Jensen K, Bjornberg O, Palfey B. Mechanism flavin reduction class 1a dihydroorotate <br />                                                  dehydrogenase lactococcus lactis. Biochemistry 2007;46(13):4028&#8211;4036. [PubMed: <br />                                                  17341096] <br />  <br />  <br />  <br />                                                   Mol Microbiol. Author manuscript; available PMC 2010 May 27. <br />                             Arakaki et al.                                                                                                     Page 13 <br />  <br />  <br />                                             Feliciano PR, Cordeiro AT, Costa-Filho AJ, Nonato MC. Cloning, expression, purification, and <br />                                                 characterization Leishmania major dihydroorotate dehydrogenase. Protein Expr Purif 2006;48(1): <br />                                                 98&#8211;103. [PubMed: 16600626] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Guda C, Lu S, Scheeff ED, Bourne PE, Shindyalov IN. CE-MC: multiple protein structure alignment <br />                                                 server. Nucleic Acids Res 2004;32:W100&#8211;W103. [PubMed: 15215359] <br />                                             Gudin S, Quashie NB, Candlish D, Al-Salabi MI, Jarvis SM, Ranford-Cartwright LC, Koning HP. <br />                                                 Trypanosoma brucei: A survey pyrimidine transport activities. Exp Parasitol 2006;114:118&#8211;125. <br />                                                 [PubMed: 16620810] <br />                                             Guex N, Peitsch MC. SWISS-MODEL Swiss-PdbViewer: environment comparative <br />                                                 protein modeling. Electrophoresis 1997;18:2714&#8211;2723. [PubMed: 9504803] <br />                                             Hall C, Brachat S, Dietrich FS. Contribution horizontal gene transfer evolution Saccharomyces <br />                                                 cerevisiae. Eukaryot Cell 2005;4(6):1102&#8211;1115. [PubMed: 15947202] <br />                                             Hansen M, Nours JL, Johansson E, Antal T, Ullrich A, L&#246;ffler M, Larsen S. Inhibitor binding class <br />                                                 2 dihydroorotate dehydrogenase causes variations membrane-associated N-terminal domain. <br />                                                 Protein Sci 2004;13:1031&#8211;1042. [PubMed: 15044733] <br />                                             Heikkil&#228; T, Thirumalairajan S, Davies M, Parsons MR, McConkey AG, Fishwick CWG, Johnson AP. <br />                                                 The novo designed inhibitors Plasmodium falciparum dihydroorotate dehydrogenase. <br />                                                 Bioorg Med Chem Lett 2006;16:88&#8211;92. [PubMed: 16236496] <br />                                             Hertz-Fowler C, Peacock CS, Wood V, Aslett M, Kerhornou A, Mooney P, Tivey A, Berriman M, Hall <br />                                                 N, Rutherford K, Parkhill J, Ivens AC, Rajandream M-A, Barrell B. GeneDB: resource for <br />                                                 prokaryotic eukaryotic organisms. Nucleic Acids Res 2004;32:D339&#8211;D343. [PubMed: <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                 14681429] <br />                                             Hirumi H, Hirumi K. Continuous cultivation Trypanosoma brucei blood stream forms medium <br />                                                 containing low concentration serum protein feeder cell layers. J Parasitol 1989;75:985&#8211; <br />                                                 989. [PubMed: 2614608] <br />                                             Holton J, Alber T. Automated protein crystal structure determination using ELVES. Proc Natl Acad Sci <br />                                                 U S A 2004;101:1537&#8211;1542. [PubMed: 14752198] <br />                                             Hurt DE, Widom J, Clardy J. Structure Plasmodium falciparum dihydroorotate dehydrogenase a <br />                                                 bound inhibitor. Acta Crystallogr D Biol Crystallogr 2006;62:312&#8211;323. [PubMed: 16510978] <br />                                             Inaoka DK, Takashima E, Osanai A, Shimizu H, Nara T, Aoki T, Harada S, Kita K. Expression, <br />                                                 purification crystallization Trypanosoma cruzi dihydroorotate dehydrogenase complexed with <br />                                                 orotate. Acta Crystallograph Sect F Struct Biol Cryst Commun 2005;61:875&#8211;878. <br />                                             Inoue M, Nakamura Y, Yasuda K, Yasaka N, <span id='am-1' about='obo:NCBITaxon_385297' typeof='owl:Thing obo:NCBITaxon_186623 obo:NCBITaxon_33213 obo:NCBITaxon_186628 obo:NCBITaxon_1 obo:NCBITaxon_186626 obo:NCBITaxon_131567 obo:NCBITaxon_186625 obo:NCBITaxon_117570 obo:NCBITaxon_89593 obo:NCBITaxon_7742 obo:NCBITaxon_117571 obo:NCBITaxon_33154 obo:NCBITaxon_7995 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_33511 obo:NCBITaxon_32519 obo:NCBITaxon_33208 obo:NCBITaxon_7711 obo:NCBITaxon_186634 obo:NCBITaxon_1489793 obo:NCBITaxon_1489341 obo:NCBITaxon_7776 obo:NCBITaxon_7898 obo:NCBITaxon_385271 obo:NCBITaxon_41665 obo:NCBITaxon_32443'><span id='am-2' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-3'  ></span><span id='am-4' property="rdfs:label" content="Hara" datatype="xsd:string"></span><span id='am-5' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>Hara</span> T, Schnaufer A, Stuart K, Fukuma T. The 14-3-3 <br />                                                 proteins Trypanosoma brucei function motility, cytokinesis, cell cycle. J Biol Chem <br />                                                 2005;280(14):14085&#8211;14096. [PubMed: 15653691] <br />                                             Karibian D. Dihydroorotate dehydrogenase (<span id='am-133' about='obo:NCBITaxon_562' typeof='owl:Thing obo:NCBITaxon_561 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_91347 obo:NCBITaxon_1224 obo:NCBITaxon_2 obo:NCBITaxon_543 obo:NCBITaxon_1236'><span id='am-134' property="oboInOwl:hasRelatedSynonym" content="Escherchia coli" datatype="xsd:string"></span><span id='am-135' property="oboInOwl:hasRelatedSynonym" content="Eschericia coli" datatype="xsd:string"></span><span id='am-136' property="oboInOwl:hasRelatedSynonym" content="Bacterium coli commune" datatype="xsd:string"></span><span id='am-137' property="oboInOwl:hasRelatedSynonym" content="Bacterium coli" datatype="xsd:string"></span><span id='am-138' property="oboInOwl:hasDbXref" content="PMID:10319482" datatype="xsd:string"></span><span id='am-139' property="oboInOwl:hasAlternativeId" content="NCBITaxon:662104" datatype="xsd:string"></span><span id='am-140' property="oboInOwl:hasDbXref" content="GC_ID:11" datatype="xsd:string"></span><span id='am-141' property="oboInOwl:hasRelatedSynonym" content="Bacillus coli" datatype="xsd:string"></span><span id='am-142' property="oboInOwl:hasExactSynonym" content="Escherichia/Shigella coli" datatype="xsd:string"></span><span id='am-143'  ></span><span id='am-144' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-145' property="oboInOwl:hasRelatedSynonym" content="bacterium E3" datatype="xsd:string"></span><span id='am-146' property="rdfs:label" content="Escherichia coli" datatype="xsd:string"></span><span id='am-147' property="oboInOwl:hasRelatedSynonym" content="Enterococcus coli" datatype="xsd:string"></span><span id='am-148' property="oboInOwl:hasAlternativeId" content="NCBITaxon:662101" datatype="xsd:string"></span>Escherichia coli</span>). Methods Enzymol 1978;51:58&#8211;63. <br />                                                 [PubMed: 211391] <br />                                             Knecht W, Bergjohann U, Gonski S, Kirschbaum B, L&#246;ffler M. Functional expression fragment of <br />                                                 human dihydroorotate dehydrogenase means baculovirus expression vector system, and <br />                                                 kinetic investigation purified recombinant enzyme. Eur J Biochem 1996;240:292&#8211;301. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                 [PubMed: 8925840] <br />                                             Laskowski RA, Chistyakov VV, Thornton JM. PDBsum more: new summaries analyses known <br />                                                 3D structures proteins nucleic acids. Nucleic Acids Res 2005;33:D266&#8211;D268. [PubMed: <br />                                                 15608193] <br />                                             Liu S, Neidhardt EA, Grossman TH, Ocain T, Clardy J. Structures human dihydroorotate <br />                                                 dehydrogenase complex antiproliferative agents. Structure 2000;8:25&#8211;33. [PubMed: <br />                                                 10673429] <br />                                             Lovell SC, Davis IW, Arendall WB, Bakker PIW, Word JM, Prisant MG, Richardson JS, Richardson <br />                                                 DC. Structure validation Calpha geometry: phi,psi Cbeta deviation. Proteins 2003;50:437&#8211; <br />                                                 450. [PubMed: 12557186] <br />                                             Luft JR, Collins RJ, Fehrman NA, Lauricella AM, Veatch CK, DeTitta GT. A deliberate approach to <br />                                                 screening initial crystallization conditions biological macromolecules. J Struct Biol <br />                                                 2003;142:170&#8211;179. [PubMed: 12718929] <br />  <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 May 27. <br />                             Arakaki et al.                                                                                                 Page 14 <br />  <br />  <br />                                             Marcinkeviciene J, Jiang W, Locke G, Kopcho LM, Rogers MJ, Copeland RA. A second dihydroorotate <br />                                                 dehydrogenase (Type A) human pathogen <span id='am-21' about='obo:NCBITaxon_1351' typeof='obo:NCBITaxon_91061 owl:Thing obo:NCBITaxon_81852 obo:NCBITaxon_1239 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_2 obo:NCBITaxon_1350 obo:NCBITaxon_186826'><span id='am-22' property="oboInOwl:hasRelatedSynonym" content="Streptococcus glycerinaceus" datatype="xsd:string"></span><span id='am-23' property="oboInOwl:hasRelatedSynonym" content="Micrococcus zymogenes" datatype="xsd:string"></span><span id='am-24' property="oboInOwl:hasRelatedSynonym" content="Micrococcus ovalis" datatype="xsd:string"></span><span id='am-25' property="oboInOwl:hasDbXref" content="GC_ID:11" datatype="xsd:string"></span><span id='am-26' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-27' property="oboInOwl:hasRelatedSynonym" content="Enterococcus proteiformis" datatype="xsd:string"></span><span id='am-28' property="rdfs:label" content="Enterococcus faecalis" datatype="xsd:string"></span><span id='am-29'  ></span><span id='am-30' property="oboInOwl:hasRelatedSynonym" content="Enterocoque" datatype="xsd:string"></span><span id='am-31' property="oboInOwl:hasAlternativeId" content="NCBITaxon:1219670" datatype="xsd:string"></span><span id='am-32' property="oboInOwl:hasRelatedSynonym" content="Streptococcus liquefaciens" datatype="xsd:string"></span><span id='am-33' property="oboInOwl:hasRelatedSynonym" content="Streptococcus faecalis" datatype="xsd:string"></span><span id='am-34' property="oboInOwl:hasRelatedSynonym" content="Enterococcus feacalis" datatype="xsd:string"></span>Enterococcus faecalis</span>: expression, purification, and <br />                                                 steady-state kinetic mechanism. Arch Biochem Biophys 2000;377(1):178&#8211;186. [PubMed: <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                 10775458] <br />                                             McRobert L, McConkey GA. RNA interference (RNAi) inhibits growth Plasmodium falciparum. Mol <br />                                                 Biochem Parasitol 2002;119(2):273&#8211;278. [PubMed: 11814579] <br />                                             Murshudov GN, Vagin <span id='am-166' about='obo:NCBITaxon_152839' typeof='owl:Thing obo:NCBITaxon_78536 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_4447 obo:NCBITaxon_4747 obo:NCBITaxon_158359 obo:NCBITaxon_158331 obo:NCBITaxon_3398 obo:NCBITaxon_1437183 obo:NCBITaxon_33090 obo:NCBITaxon_158350 obo:NCBITaxon_73496 obo:NCBITaxon_131221 obo:NCBITaxon_58024 obo:NCBITaxon_58023 obo:NCBITaxon_2759 obo:NCBITaxon_35493 obo:NCBITaxon_1437197 obo:NCBITaxon_3193'><span id='am-167' property="rdfs:label" content="Aa" datatype="xsd:string"></span><span id='am-168' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-169' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-170' property="oboInOwl:hasRelatedSynonym" content="Aa Rchb.f." datatype="xsd:string"></span><span id='am-171'  ></span>AA</span>, Dodson EJ. Refinement macromolecular structures maximum- <br />                                                 likelihood method. Acta Cryst 1997;D53:240&#8211;255. <br />                                             Nara T, Hshimoto T, Aoki T. Evolutionary implications mosaic pyrimidine-biosynthetic pathway <br />                                                 eukaryotes. Gene 2000;257:209&#8211;222. [PubMed: 11080587] <br />                                             Nielsen FS, Andersen PS, Jensen KF. The B form dihydroorotate dehydrogenase Lactococcus <br />                                                 lactis consists different subunits, encoded pyrDb pyrK genes, contains FMN, <br />                                                 FAD, [FeS] redox centers. J Biol Chem 1996;271:29359&#8211;29365. [PubMed: 8910599] <br />                                             Nielsen FS, Rowland P, Larsen S, Jensen KF. Purification characterization dihydroorotate <br />                                                 dehydrogenase A Lactococcus lactis, crystallization preliminary X-ray diffraction studies <br />                                                 enzyme. Protein Sci 1996;5:852&#8211;856. [PubMed: 8732756] <br />                                             N&#248;rager S, Arent S, Bj&#246;rnberg O, Ottosen M, Leggio LL, Jensen KF, Larsen S. Lactococcus lactis <br />                                                 dihydroorotate dehydrogenase A mutants reveal important facets enzymatic function. J Biol <br />                                                 Chem 2003;278:28812&#8211;28822. [PubMed: 12732650] <br />                                             Palfey BA, Bj&#246;rnberg O, Jensen KF. Specific inhibition family 1A dihydroorotate dehydrogenase <br />                                                 benzoate pyrimidine analogues. J Med Chem 2001;44:2861&#8211;2864. [PubMed: 11520193] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Papageorgiou IG, Yakob L, Salabi MIA, Diallinas G, Soteriadou KP, Koning HPD. Identification the <br />                                                 pyrimidine nucleobase transporter Leishmania: similarities Trypanosoma brucei U1 <br />                                                 transporter antileishmanial activity uracil analogues. Parasitology 2005;130:275&#8211;283. <br />                                                 [PubMed: 15796010] <br />                                             Raz B, Iten M, Grether-Buhler Y, Kaminsky R, Brun R. The Alamar Blue assay determine drug <br />                                                 sensitivity African trypanosomes (T.b. rhodesiense T.b. gambiense) vitro. Acta Trop <br />                                                 1997;68(2):139&#8211;147. [PubMed: 9386789] <br />                                             Redmond S, Vadivelu J, Field MC. RNAit: automated web-based tool selection RNAi targets <br />                                                 Trypanosoma brucei. Mol Biochem Parasitol 2003;128:115&#8211;118. [PubMed: 12706807] <br />                                             Rowland P, N&#248;rager S, Jensen KF, Larsen S. Structure dihydroorotate dehydrogenase B: electron <br />                                                 transfer flavin groups bridged iron-sulphur cluster. Structure 2000;8:1227&#8211;1238. <br />                                                 [PubMed: 11188687] <br />                                             Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: An automated protein homology-modeling <br />                                                 server. Nucleic Acids Res 2003;31:3381&#8211;3385. [PubMed: 12824332] <br />                                             Takashima E, Inaoka DK, Osanai A, Nara T, Odaka M, Aoki T, Inaka K, Harada S, Kita K. <br />                                                 Characterization dihydroorotate dehydrogenase soluble fumarate reductase in <br />                                                 Trypanosoma cruzi. Mol Biochem Parasitol 2002;122(2):189&#8211;200. [PubMed: 12106873] <br />                                             Vagin A, Teplyakov A. Molrep: automated program molecular replacement. J. Appl. Cryst <br />                                                 1997;30:1022&#8211;1025. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Wang CC. Validating targets antiparasite chemotherapy. Parasitology 1997;114:S31&#8211;S44. Suppl <br />                                                 (NIL). [PubMed: 9309767] <br />                                             Wirtz E, Leal S, Ochatt C, Cross GA. A tightly regulated inducible expression conditional <br />                                                 gene knock-outs dominant-negative genetics Trypanosoma brucei. Mol Biochem Parasitol <br />                                                 1999;99:89&#8211;101. [PubMed: 10215027] <br />                                             Wolfe A, Thymark M, Gattis S, Fagan R, Hu Y-c, Johansson E, Arent S, Larsen S, Palfey B. Interaction <br />                                                 benzoate pyrimidine analogues class 1a dihydroorotate dehydrogenase lactococcus <br />                                                 lactis. Biochemistry 2007;46(19):5741&#8211;5753. [PubMed: 17444658] <br />  <br />  <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 May 27. <br />                             Arakaki et al.                                                                          Page 15 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Figure 1. <br />                                             Oxidation dihydroorotate orotate. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 May 27. <br />                             Arakaki et al.                                                                                        Page 16 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Figure 2. <br />                                             Comparison T. brucei human DHODH. TbDHODH homodimeric, typical Class <br />                                             1A homologues. The human enzyme monomeric, characteristic Class 2 homologues. <br />                                             (a) TbDHODH monomer showing Class 1A motifs: Motif 1 (residues 195&#8211;203, blue), Motif <br />                                             2 (residues 64&#8211;76, green), Motif 3 (residues 214&#8211;223, orange), Pyr-binding motif (residues <br />                                             126&#8211;143, red). The orotate FMN cofactors shown brown yellow, respectively. <br />                                             (b) Surface representation TbDHODH, showing orotate FMN sites relatively <br />                                             solvent accessible loop 132&#8211;138 &#8216;closed&#8217; conformation. (c) Surface <br />                                             representation entire human DHODH monomer including well-ordered residues (30&#8211; <br />                                             69) N-terminal domain (brown). In Class 2 homologues N-terminal domain <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 May 27. <br />                             Arakaki et al.                                                                                             Page 17 <br />  <br />  <br />                                             restricts solvent access orotate FMN binding sites direction. The depression <br />                                             visible center surface binding site Class 2 DHODH redox partner <br />                                             ubiquinone, Class 2 specific inhibitors brequinar. (d) Surface representation <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             human DHODH N-terminal residues removed purpose comparison the <br />                                             trypanosomal enzyme. <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 May 27. <br />                             Arakaki et al.                                                                                          Page 18 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Figure 3. <br />                                             A structure-based sequence alignment Class 1A T. brucei (current structure), Class <br />                                             1B L. lactis (PDB accession code 1ep1), Class 2 human DHODH (PDB accession code <br />                                             1d3g). The active site Cys131 colored yellow. Four Asn residues important catalysis and <br />                                             conserved classes DHODH colored cyan. Three Class 1A motifs further <br />                                             aid classification DHODHs labeled discussed Fig. S2. Residue <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             numbering secondary structure elements correspond T. brucei DHODH. The <br />                                             alignment generated using CEMC Multiple Protein Structure Alignment Server <br />                                             (http://bioinformatics.albany.edu/~cemc/) (Guda et al., 2004) colored using TEXshade <br />                                             (Beitz, 2000). The human sequence shown begins residue 69, omitting N-terminal <br />                                             domain present Class 1 homologues. <br />  <br />  <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 May 27. <br />                             Arakaki et al.                                                                                              Page 19 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Figure 4. <br />                                             Knockdown DHODH mRNA expression (Panel A) DHODH protein expression (Panel <br />                                             B) induction RNAi tetracycline. (A - top) Northern blot T. brucei cells collected <br />                                             72 h post-tetracycline induction RNAi (TCN+) demonstrates 95% knockdown DHODH <br />                                             mRNA compared cells containing construct RNAi uninduced (TCN-). (A - <br />                                             bottom) &#946;-tubulin mRNA expression levels near-equivalent RNA loading. (B) A Western <br />                                             blot performed cell lysates collected day 0 (pre-induction) 7 days post- <br />                                             induction. The blot probed anti-T. brucei DHODH antibody. The upper band <br />                                             represents binding <span id='am-187' about='obo:NCBITaxon_32644' typeof='owl:Thing obo:NCBITaxon_12908 obo:NCBITaxon_1'><span id='am-188' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-189' property="oboInOwl:hasRelatedSynonym" content="unidentified organism" datatype="xsd:string"></span><span id='am-190' property="oboInOwl:hasRelatedSynonym" content="other" datatype="xsd:string"></span><span id='am-191' property="oboInOwl:hasRelatedSynonym" content="unclassified sequence" datatype="xsd:string"></span><span id='am-192' property="oboInOwl:hasRelatedSynonym" content="sonstige nucleic acid" datatype="xsd:string"></span><span id='am-193'  ></span><span id='am-194' property="oboInOwl:hasRelatedSynonym" content="not specified" datatype="xsd:string"></span><span id='am-195' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-196' property="oboInOwl:hasRelatedSynonym" content="unknwon" datatype="xsd:string"></span><span id='am-197' property="oboInOwl:hasRelatedSynonym" content="miscellaneous nucleic acid" datatype="xsd:string"></span><span id='am-198' property="oboInOwl:hasRelatedSynonym" content="none" datatype="xsd:string"></span><span id='am-199' property="oboInOwl:hasRelatedSynonym" content="unknown organism" datatype="xsd:string"></span><span id='am-200' property="oboInOwl:hasRelatedSynonym" content="unspecified" datatype="xsd:string"></span><span id='am-201' property="oboInOwl:hasRelatedSynonym" content="not shown" datatype="xsd:string"></span><span id='am-202' property="rdfs:label" content="unidentified" datatype="xsd:string"></span><span id='am-203' property="oboInOwl:hasRelatedSynonym" content="unknown" datatype="xsd:string"></span>unidentified</span> protein affected RNAi expression. The <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             predicted DHODH protein labelled nearly absent day induction RNAi. <br />  <br />  <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 May 27. <br />                             Arakaki et al.                                                                                           Page 20 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Figure 5. <br />                                             Gene knockdown T. brucei DHODH using RNA interference. Cumulative cell densities are <br />                                             shown log-scale product cell number total dilution. (A). Cell growth <br />                                             monitored T. brucei undergoing RNAi DHODH (TCN+) compared cells <br />                                             RNAi induction (TCN&#8722;). The cells grown standard media bloodstream- <br />                                             form T. brucei. The growth rate compared &quot;single marker&quot; (SM) strain T. <br />                                             brucei transfected RNAi expression vector (semi-logarithmic plot). (B). <br />                                             The experiment Panel A repeated using pyrimidine-depleted medium. <br />  <br />  <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 May 27. <br />                             Arakaki et al.                                                                                           Page 21 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Figure 6. <br />                                             Effects different concentrations 5-FU T. brucei cells. RNAi induced with <br />                                             tetracycline 48 h, cells incubated serial dilutions 5-FU 48 h <br />                                             quantified Alamar Blue. Labeling Figure 5. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 May 27. <br />                             Arakaki et al.                                                                                        Page 22 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Figure 7. <br />                                             Incorporation (3H)5-FU T. brucei cells. RNAi induced tetracycline 72 h, <br />                                             cells exposed (3H)5-FU additional 24 h harvesting quantifying <br />                                             tritium uptake DNA. Labeling Figure 5. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 May 27. <br />                             Arakaki et al.                                                                                    Page 23 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Figure 8. <br />                                             Terminal electron acceptor preference TbDHODH. Activity examined presence <br />                                             250 &#181;M DHO 100 &#181;M electron acceptor ~210 &#181;M molecular oxygen. The kcatapp is <br />                                             apparent kcat obtained fixed concentration DHO (0.25 mM) oxidant. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 May 27. <br />                             Arakaki et al.                                                                                        Page 24 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Figure 9. <br />                                             Saturation kinetics T. brucei DHODH DHO fumarate. DHO-dependent activity <br />                                             assayed presence 500 &#181;M fumarate fumarate-dependent activity assayed <br />                                             presence 250 &#181;M DHO pH 8. Vmax 8.5 s&#8722;1, Km DHO 14 &#181;M, Km for <br />                                             fumarate 80 &#181;M. The kcatapp apparent kcat obtained fixed concentration one <br />                                             substrate varied. Inset: pH-dependent T. brucei DHODH activity. Activity <br />                                             determined presence 125 &#181;M DHO 500 &#181;M fumarate. Activity peaks pH <br />                                             7.8 curve indicates ionizable groups pKa values 6.3 9.2. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 May 27. <br />                             Arakaki et al.                                                                                    Page 25 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Figure 10. <br />                                             Ping-pong kinetics T. brucei DHODH. Double-reciprocal plot DHO-dependent activity <br />                                             presence varying concentrations fumarate 5 nM T. brucei DHODH produce <br />                                             parallel lines indicative ping-pong enzyme mechanism. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 May 27. <br />                             Arakaki et al.                                                                                      Page 26 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Figure 11. <br />                                             Inhibition TbDHODH 3,4- 3,5-dihydroxybenzoate. Activity determined varying <br />                                             concentrations DHO inhibitor 5 nM T. brucei DHODH. Double reciprocal plots <br />                                             characteristic competitive inhibition indicated concentrations 3,4 <br />                                             dihydroxybenzoate (a) non-competitive inhibition 3,5 dihydroxybenzoate (b). <br />  <br />  <br />  <br />  <br />                           <br /> </body></html>